Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Clinical trial NCT05166577 · TERMINATED
Trial details
- NCT number
- NCT05166577
- Sponsor
- Viracta Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-08
- Primary completion
- 2024-10-30
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.